Qin Gao Selected Research

Atractyloside

1/2012	[The role of nitric oxide in ethanol postconditioning induced cardioprotection].
11/2010	[Activation of mitochondrial aldehyde dehydrogenase 2 and inhibition of mitochondrial permeability transition pore involved in cardioprotection of ethanol postconditioning].
11/2006	[The protective role and the mechanisms of puerarin on isolated rat heart during ischemia/reperfusion].
9/2006	Kappa-opioid receptors mediate cardioprotection by remote preconditioning.
6/2006	Atractyloside and 5-hydroxydecanoate block the protective effect of puerarin in isolated rat heart.
12/2005	The mitochondrial permeability transition pore and the Ca2+-activated K+ channel contribute to the cardioprotection conferred by tumor necrosis factor-alpha.
1/2005	Improvement of ventricular mechanical properties by puerarin involves mitochondrial permeability transition in isolated rat heart during ischemia and reperfusion.
1/2005	[Cardioprotection of mitoSlo1 channel activation involves mitochondrial permeability transition in ischemia and reperfusion of rat hearts].

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Qin Gao Research Topics

Disease

29	Ischemia 01/2020 - 01/2005
27	Reperfusion Injury 01/2022 - 01/2005
21	Neoplasms (Cancer) 12/2021 - 05/2010
20	Infarction (Infarctions) 01/2020 - 01/2005
15	Myocardial Ischemia (Ischemic Heart Diseases) 01/2022 - 09/2006
12	Diabetes Mellitus 01/2021 - 10/2012
11	Body Weight (Weight, Body) 01/2020 - 10/2012
8	Inflammation (Inflammations) 11/2022 - 05/2016
8	Gestational Diabetes (Gestational Diabetes Mellitus) 06/2021 - 01/2017
7	Fibrosis (Cirrhosis) 04/2020 - 01/2016
6	Cardiovascular Diseases (Cardiovascular Disease) 11/2022 - 01/2018
6	Alzheimer Disease (Alzheimer's Disease) 06/2021 - 12/2004
5	Wounds and Injuries (Trauma) 01/2021 - 01/2012
4	Neurodegenerative Diseases (Neurodegenerative Disease) 06/2021 - 10/2013
4	Myocardial Infarction 09/2020 - 06/2013
3	Infections 04/2022 - 01/2021
3	Lung Injury 01/2022 - 11/2012
3	Cardiac Arrhythmias (Arrythmia) 01/2022 - 01/2005
3	Hypertension (High Blood Pressure) 10/2021 - 04/2013
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2021 - 01/2012
3	Type 2 Diabetes Mellitus (MODY) 01/2021 - 04/2013
3	Necrosis 01/2021 - 10/2016
3	Diabetic Cardiomyopathies 01/2020 - 10/2012
3	Insulin Resistance 01/2020 - 04/2013
3	Hyperthermia 01/2019 - 01/2018
3	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 04/2017 - 11/2015
3	Polycystic Ovary Syndrome (Syndrome, Stein-Leventhal) 04/2008 - 05/2005
2	Respiratory Tract Infections (Respiratory Tract Infection) 05/2022 - 01/2020
2	Sepsis (Septicemia) 01/2022 - 08/2016
2	Lung Neoplasms (Lung Cancer) 12/2021 - 12/2020
2	Endometrial Neoplasms (Endometrial Cancer) 01/2021 - 05/2014
2	Hypoxia (Hypoxemia) 01/2021 - 11/2010
2	Prostatic Neoplasms (Prostate Cancer) 01/2021 - 01/2019
2	Cardiotoxicity 01/2021 - 01/2019

Drug/Important Bio-Agent (IBA)

17	Proteins (Proteins, Gene)FDA Link 01/2022 - 05/2010
15	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 10/2016 - 01/2005
11	Messenger RNA (mRNA)IBA 04/2020 - 05/2010
11	Mitochondrial Permeability Transition PoreIBA 05/2018 - 01/2005
10	Pharmaceutical PreparationsIBA 01/2022 - 12/2004
9	Glucose (Dextrose)FDA LinkGeneric 01/2021 - 02/2008
8	Ethanol (Ethyl Alcohol)IBA 01/2019 - 11/2010
8	AtractylosideIBA 01/2012 - 01/2005
7	Blood Glucose (Blood Sugar)IBA 04/2020 - 10/2012
7	FormazansIBA 05/2008 - 01/2005
6	salicylhydroxamic acid (SHAM)IBA 01/2020 - 05/2010
5	Interleukin-6 (Interleukin 6)IBA 01/2022 - 08/2017
5	InflammasomesIBA 01/2021 - 05/2016
5	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2020 - 02/2005
5	KATP ChannelsIBA 11/2010 - 01/2005
5	puerarinIBA 11/2010 - 01/2005
4	EnzymesIBA 01/2022 - 01/2003
4	Mitochondrial Aldehyde DehydrogenaseIBA 01/2022 - 03/2012
4	HydrogelsIBA 12/2021 - 10/2017
4	Biomarkers (Surrogate Marker)IBA 12/2020 - 01/2012
4	triphenyltetrazoliumIBA 01/2020 - 09/2006
4	LipopolysaccharidesIBA 01/2019 - 01/2005
4	Caspase 3 (Caspase-3)IBA 05/2018 - 10/2012
4	Streptozocin (Streptozotocin)FDA Link 04/2017 - 11/2015
4	Superoxide DismutaseIBA 10/2016 - 02/2005
4	5-hydroxydecanoic acidIBA 11/2010 - 01/2005
3	IronIBA 11/2022 - 12/2020
3	AldehydesIBA 01/2022 - 04/2013
3	rho-Associated KinasesIBA 01/2022 - 12/2016
3	Interleukin-18 (Interleukin 18)IBA 11/2021 - 01/2020
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2021 - 02/2015
3	Irbesartan FDA LinkGeneric 01/2021 - 03/2016
3	PolyphenolsIBA 01/2021 - 06/2012
3	Volatile Organic CompoundsIBA 01/2021 - 01/2019
3	CholesterolIBA 04/2020 - 05/2018
3	Triglycerides (Triacylglycerol)IBA 04/2020 - 05/2018
3	fasudil (AT 877)IBA 01/2020 - 12/2016
3	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2020 - 11/2007
3	Therapeutic UsesIBA 02/2019 - 10/2017
3	Aldehyde DehydrogenaseIBA 01/2019 - 03/2012
3	endomorphin 1IBA 05/2018 - 10/2016
3	Dexmedetomidine FDA Link 01/2018 - 07/2016
3	sodium bisulfide (NaHS)IBA 04/2017 - 02/2016
3	Nitric Oxide Synthase (NO Synthase)IBA 01/2012 - 01/2005
3	Calcium-Activated Potassium Channels (Calcium-Activated Potassium Channel)IBA 11/2010 - 01/2007
3	paxillineIBA 11/2010 - 02/2005
3	SpermineIBA 07/2009 - 08/2006
3	NS 1619IBA 12/2005 - 01/2005
2	Vitamin D FDA LinkGeneric 05/2022 - 01/2020
2	Oxygen (Dioxygen)IBA 12/2021 - 11/2012
2	MicroRNAs (MicroRNA)IBA 12/2021 - 03/2019
2	AntioxidantsIBA 10/2021 - 02/2005
2	CytokinesIBA 01/2021 - 11/2012
2	Prostate-Specific Antigen (Semenogelase)IBA 01/2021 - 01/2019
2	anlotinibIBA 01/2021 - 12/2020
2	Long Noncoding RNAIBA 01/2021 - 05/2014
2	LipidsIBA 12/2020 - 05/2018

Therapy/Procedure

9	Ischemic Postconditioning 01/2020 - 01/2007
9	Therapeutics 07/2019 - 05/2005
8	Ligation 01/2022 - 01/2005
5	Punctures 01/2022 - 01/2005
4	Injections 12/2021 - 10/2017
4	Precision Medicine 09/2020 - 01/2018
3	Radiotherapy 12/2021 - 01/2021
3	Drug Therapy (Chemotherapy) 01/2021 - 10/2017
3	Lasers (Laser) 09/2020 - 01/2018